Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The Chemotherapy Regimen IVAC Is Highly Active for Multiply Relapsed and Refractory Hodgkin Lymphoma

Catherine S. Diefenbach, MD, David Kaminetzky, MD, Shannon Andersen, MSN, NP, Jane Chin, NP, Barbara MacGregor-Cortelli, BSN, RN, OCN, Jasmine M Zain, MD

Blood (2012) 120 (21): 4863.

https://doi.org/10.1182/blood.V120.21.4863.4863

Published: 2012

Journal Articles

Safety and Management of Pralatrexate Treatment in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL).

Lauren Pinter-Brown, Steven M. Horwitz, MD, Barbara Pro, MD, Pier Luigi Zinzani, MD, Christian Gisselbrecht, MD, Barbara MacGregor Cortelli, RN, Steven Fruchtman, MD, Owen A O'Connor, MD, PhD

Blood (2009) 114 (22): 1675.

https://doi.org/10.1182/blood.V114.22.1675.1675

Published: 2009

Journal Articles

Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions

Alexander G. Marneros, Marc E. Grossman, David N. Silvers, Sameera Husain, Gerard J. Nuovo, Barbara MacGregor-Cortelli, Ellen Neylon, Molly Patterson, Owen A. O'Connor, Jasmine M. Zain

Blood (2009) 113 (25): 6338–6341.

https://doi.org/10.1182/blood-2009-03-210989

Published: 2009

Journal Articles

Drug-Induced Cutaneous Vasculitis in Patients with Non-Hodgkin’s Lymphoma Receiving Bortezomib: A Possible Surrogate Marker of Response.

John Gerecitano, MD, PhD, Andre Goy, MD, Barbara MacGregor-Cortelli, OCN, Ellen Neylon, John Wright, MD, PhD, Dixie Esseltine, MD, David Schenkein, MD, Mithat Gonen, PhD, Owen A. O’Connor, MD, PhD

Blood (2005) 106 (11): 3334.

https://doi.org/10.1182/blood.V106.11.3334.3334

Published: 2005

Journal Articles

A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition.

Owen O’Connor, MD, PhD, John Wright, Craig Moskowitz, MD, Barbara MacGregor-Cortelli, RN, David Straus, MD, Andrew Evans, MD, Jane Winter, MD, Omer Koc, MD, Nancy Horvath, RN, Susan Blumel, MD, Julie Vose, MD, David Schenkein, MD, Andrew Zelenetz, MD

Blood (2004) 104 (11): 607.

https://doi.org/10.1182/blood.V104.11.607.607

Published: 2004

NARROW

The Chemotherapy Regimen IVAC Is Highly Active for Multiply Relapsed and Refractory Hodgkin Lymphoma

Safety and Management of Pralatrexate Treatment in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL).

Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions

Drug-Induced Cutaneous Vasculitis in Patients with Non-Hodgkin’s Lymphoma Receiving Bortezomib: A Possible Surrogate Marker of Response.

A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition.

Email alerts

ASH Publications

American Society of Hematology

The Chemotherapy Regimen IVAC Is Highly Active for Multiply Relapsed and Refractory Hodgkin Lymphoma

Safety and Management of Pralatrexate Treatment in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL).

Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions

Drug-Induced Cutaneous Vasculitis in Patients with Non-Hodgkin’s Lymphoma Receiving Bortezomib: A Possible Surrogate Marker of Response.

A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only